Incannex Healthcare Appoints Alison Wimms, Ph.D. to its Newly Formed IHL-42X Obstructive Sleep Apnea Clinical Advisory Board

Incannex Healthcare Inc. (NASDAQ: IXHL) recently announced a key appointment within its organization. On February 4, 2025, the company appointed Alison Wimms, Ph.D. to the newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board. Dr. Wimms, with significant industry and clinical development experience in sleep medicine innovation, brings valuable expertise to her new role.

Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, along with Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. Her two decades of experience in the sleep medicine industry and research make her a welcome addition to Incannex’s advisory board.

Joel Latham, President and Chief Executive Officer of Incannex, expressed excitement about the appointment, stating, “Incannex’s newly formed clinical advisory board and the appointment of Dr. Wimms underscore our continued dedication to innovation in the field of OSA and transforming patient treatment outcomes.”

The appointment comes as Incannex advances its IHL-42X, an oral fixed-dose combination of acetazolamide and dronabinol, currently undergoing Phase 2/3 clinical studies for OSA treatment. This innovative drug targets distinct physiological pathways associated with OSA, aiming to improve patient outcomes significantly.

Dr. Wimms also expressed enthusiasm for joining Incannex’s OSA Clinical Advisory Board, emphasizing her commitment to advising on IHL-42X late-stage clinical development, further showcasing the continued progress and dedication of Incannex in the field of sleep medicine innovation.

The company’s development efforts have been focused on creating novel oral fixed-dose treatments targeting chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder. The appointment of Dr. Wimms aligns with Incannex’s commitment to advancing its clinical programs and driving innovation in the healthcare sector.

Investors and stakeholders can find more insights into Incannex Healthcare’s recent developments in its press release dated February 4, 2025.

This announcement signifies a strategic move by Incannex Healthcare to enhance its expertise and capabilities in the OSA treatment space, setting the stage for further advancements in patient care and therapeutic innovation.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Incannex Healthcare’s 8K filing here.

Incannex Healthcare Company Profile

Incannex Healthcare Inc, a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications.